Fludin1%

Fludin ophthalmic solution is an antiviral eye drop with the following established indications:

• Primary keratoconjunctivitis caused by herpes simplex virus (HSV) types 1 and 2 (FDA-approved).
• Recurrent epithelial keratitis caused by herpes simplex virus types 1 and 2 (FDA-approved).

Fludin is indicated only for herpetic epithelial keratitis; it is not effective against deeper (stromal) herpetic eye disease, bacterial, fungal, chlamydial, or Acanthamoeba keratitis, and is not a substitute for evaluation and diagnosis by an ophthalmologist.

Each mL of Trifluridine ophthalmic solution contains 10 mg (1% w/v) of trifluridine as the active ingredient, along with inactive ingredients such as sodium chloride, sodium hydroxide and/or hydrochloric acid (for pH adjustment), a preservative (e.g., thimerosal), and purified water. Exact excipients may vary slightly by manufacturer; refer to the specific product label.

Fludin is a fluorinated pyrimidine nucleoside analog with antiviral activity against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), and some in-vitro activity against vaccinia virus and certain adenovirus strains. It is formulated as a sterile 1% ophthalmic solution for topical use in the eye and is used specifically to treat herpetic infections of the corneal epithelium.

Fludin was one of the first topical antivirals developed for herpetic eye disease and remains a treatment option, including for infections that respond poorly to other topical antivirals.

Fludin belongs to the ophthalmic antiviral therapeutic class, specifically the pyrimidine nucleoside analogue antivirals used topically in the eye.

Trifluridine is a fluorinated pyrimidine nucleoside analogue of thymidine. After entering virus-infected corneal epithelial cells, it is phosphorylated by cellular and viral thymidine kinase to its active triphosphate form. This active metabolite is incorporated into viral (and, to a lesser extent, host cell) DNA in place of thymidine, and it also inhibits thymidylate synthetase, an enzyme required for DNA synthesis. The combined effect disrupts viral DNA replication and halts reproduction of herpes simplex virus within infected cells.

Following topical ophthalmic administration, systemic absorption of Trifluridine is minimal, and the drug acts primarily at the site of application on the corneal surface. Some herpes simplex strains that develop resistance to other antivirals (e.g., idoxuridine) retain sensitivity to Trifluridine, making it a useful option in certain refractory cases.

Fludin is for topical ophthalmic (eye) use only and must never be injected or taken by mouth. Instill the drop into the conjunctival sac of the affected eye, avoiding contact between the dropper tip and the eye or any other surface to prevent contamination. See Dosage & Administration above for the full instillation technique and dosing frequency.

Because Fludin ophthalmic solution has minimal systemic absorption when used as directed, clinically significant systemic drug interactions have not been well established.

• Other topical ophthalmic medications: Using Fludin together with other eye drops or ointments (including other antivirals, antibiotics, or corticosteroids) may reduce the effect of each product or increase local irritation; separate applications by at least 5-10 minutes and inform the prescriber of all eye medications in use.
• Topical corticosteroids: Concurrent use of topical steroids with Fludin for herpetic keratitis should only be done under close ophthalmologist supervision, as steroids can worsen herpetic epithelial disease if not properly managed.

The most common side effect of Fludin is mild, transient burning or stinging of the eye upon instillation. Other reported adverse effects include:

• Palpebral (eyelid) edema
• Superficial punctate keratopathy and other corneal epithelial changes
• Stromal edema of the cornea
• Hyperemia (redness) of the conjunctiva
• Increased intraocular pressure (uncommon)
• Hypersensitivity/allergic reactions of the eye or eyelid

Prolonged continuous use of Fludin beyond 21 days increases the risk of corneal toxicity (see Precautions & Warnings). Patients should promptly report worsening eye pain, vision changes, or increasing redness to their ophthalmologist.

Pregnancy: There are no adequate and well-controlled studies of Fludin in pregnant women. Although systemic absorption after topical ophthalmic use is minimal, Fludin should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use in pregnancy.

Lactation: It is not known whether topically applied Fludin is excreted in human breast milk. Because many drugs are excreted in breast milk, caution should be exercised and a physician consulted before using Fludin while breastfeeding.

Ophthalmologist supervision required: Fludin should be used only under the supervision of an ophthalmologist, with regular follow-up to confirm re-epithelialization and monitor for complications.

• Duration limit: Continuous use beyond 21 days is not recommended because of the risk of ocular toxicity (e.g., corneal changes, punctate keratopathy).
• Not effective against non-herpetic infections: Fludin has no proven efficacy against bacterial, fungal, chlamydial, or Acanthamoeba eye infections; using it for these conditions delays appropriate treatment.
• Confirm healing: If improvement does not occur within 7-14 days, or if the condition worsens, the diagnosis and treatment plan should be re-evaluated by an ophthalmologist.
• Contact lenses: Soft contact lenses should not be worn during active herpetic keratitis or treatment with Fludin.
• Driving/vision: Transient blurred vision may occur immediately after instillation; wait until vision clears before driving or operating machinery.

Ocular overdose (accidental application of excess drops) with Fludin is unlikely to cause serious systemic toxicity because systemic absorption from the eye is minimal, but it may increase local irritation and the risk of corneal toxicity with repeated excess use. If Fludin is accidentally swallowed or a significant overdose is suspected, contact a physician, hospital emergency department, or poison control center immediately for guidance; do not attempt home treatment for a suspected ingestion.

Store Fludin ophthalmic solution under refrigeration, between 2°C and 8°C (36°F to 46°F), unless the manufacturer's label states otherwise. Protect from light, keep the bottle tightly closed when not in use, discard any unused solution after the manufacturer-specified period once opened, and keep out of reach of children.

Pediatric patients: The safety and efficacy of Fludin have not been established in children younger than 6 years of age. In children 6 years and older, dosing is the same as in adults, under close ophthalmologist supervision.

Elderly patients: No specific dose adjustment is required for elderly patients; efficacy and safety are similar to that seen in younger adults.

Renal or hepatic impairment: No dose adjustment is required for renal or hepatic impairment, as systemic absorption of topically applied Fludin is minimal.

Immunocompromised patients: Herpetic keratitis may be more severe or resistant to treatment in immunocompromised patients; close ophthalmologist follow-up is advised.

Treatment with Fludin is continued until the corneal epithelial defect has completely healed (re-epithelialized), typically within 7-14 days, followed by a reduced-frequency maintenance course of 7 additional days. Continuous therapy with Fludin should not exceed 21 days because of the increased risk of corneal toxicity with prolonged use; if healing is incomplete by then, the diagnosis and treatment plan should be reassessed by an ophthalmologist.

Antiviral agent - ophthalmic pyrimidine nucleoside analogue.

Trifluridine is phosphorylated intracellularly to trifluridine triphosphate, which is incorporated into viral DNA in place of thymidine and also inhibits thymidylate synthetase, thereby blocking replication of herpes simplex virus in infected corneal cells. See Pharmacology for full mechanistic detail.

C

The safety and efficacy of Fludin ophthalmic solution have not been established in children younger than 6 years of age. For children aged 6 years and older, the same dosage as adults is used (1 drop every 2 hours while awake, maximum 9 drops/day, until re-epithelialization, then 1 drop every 4 hours for 7 more days), under the direct supervision of an ophthalmologist. Caregivers should ensure proper instillation technique to avoid contamination of the dropper tip and should seek prompt medical review if the child's eye condition worsens or fails to improve.